Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397449 | 0.98 | ACHE (0.30) | ACHE | |
| SCHEMBL3397730 | 0.95 | ACHE (0.31) | ACHE | |
| SCHEMBL3398757 | 0.91 | ACHE (0.36) | ACHE | |
| SCHEMBL3402313 | 0.89 | ACHE (0.35) | ACHE | |
| SCHEMBL3403369 | 0.89 | ACHE (0.33) | ACHE | |
| SCHEMBL13762883 | 0.80 | — | — | |
| SCHEMBL13071253 | 0.77 | — | — | |
| SCHEMBL3397363 | 0.76 | — | — | |
| SCHEMBL3398758 | 0.70 | — | — | |
| SCHEMBL3403134 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-8765739-B2 | Azetidine compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2684861-A2 | Spiro compounds and pharmaceutical use thereof | Japan Tobacco Inc. (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2508503-A1 | Spiro compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2202216-B1 | SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-2431365-A1 | AZETIDINE COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2010131738-A1 | AZETIDINE COMPOUND AND MEDICINAL USE THEREOF | 日本たばこ産業株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
| EP-2202216-A1 | SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco Inc. (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | ACHE 3334/4885 |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | ACHE 3334/4885 |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | ACHE 3334/4885 |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP2C9, QDPR | ACHE 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.